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OBJECTIVE — We investigated how -cell function and insulin sensitivity or resistance are
affected by the type of blood sample collected or choice of insulin assay and homeostatis model
assessment (HOMA) calculator (http://www.dtu.ox.ac.uk).
RESEARCH DESIGN AND METHODS — Insulin was measured using 11 different
assays in serum and 1 assay in heparinized plasma. Fasting subjects with normoglycemia (n 
12), pre-diabetes, i.e., impaired fasting glucose or impaired glucose tolerance (n  18), or type
2 diabetes (n  67) were recruited. Patients treated with insulin or those who were insulin
antibody–positivewereexcluded.HOMAestimateswerecalculatedusingspeciﬁcinsulin(SI)or
radioimmunoassay (RIA) calculators (version 2.2).
RESULTS — All glucose values were within model (HOMA) limits but not all insulin results,
as 4.3% were 20 pmol/l and 1% were 300 pmol/l. -Cell function derived from different
insulin assays ranged from 67 to 122% (median) for those with normoglycemia (P  0.026),
from89to138%forthosewithpre-diabetes(P0.990),andfrom50to81%forthosewithtype
2 diabetes (P  0.0001). Furthermore, insulin resistance ranged from 0.8 to 2.0 (P  0.0007),
from 1.9 to 3.2 (P  0.842), and from 1.5 to 2.9 (P  0.0001), respectively. This twofold
variationinHOMAestimatesfromthevariousinsulinassaysstudiedinserummaybesigniﬁcant
metabolically. Insulin was 15% lower in heparinized plasma (used in the original HOMA study)
comparedwithserum,whichisnowmorecommonlyused.-Cellfunctiondifferedby11%and
insulinresistanceby15%whenestimatesderivedfromspeciﬁcinsulinwerecalculatedusingthe
RIA rather than the SI calculator.
CONCLUSIONS — To enable comparison of HOMA estimates among individuals and dif-
ferentresearchstudies,preanalyticalfactorsandcalculatorselectionshouldbestandardizedwith
insulin assays traceable to an insulin reference method procedure.
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H
omeostasis model assessment
(HOMA) is widely used to calculate
insulin resistance (HOMA-IR), and
-cell function (HOMA-), from con-
comitant glucose and insulin (or C-
peptide) in fasting subjects (1,2). There is
growingrecognitionthatinterpretationof
HOMA estimates (3) may not be appro-
priate in some circumstances because
insufﬁcient information is available on
effects of preanalytical factors, insulin
assays, or version of HOMA calculator
selected. These parameters are deﬁned
within studies and are therefore stable
but may differ between studies, mak-
ing application of HOMA to individuals
and comparison of research studies
problematic.
The current HOMA speciﬁc insulin
(SI) and radioimmunoassay (RIA) calcu-
lators (version 2.2) evolved from com-
puter models that replaced equations
derived from the original computer
model published in 1985 (Table 1). The
HOMA RIA calculator was originally de-
velopedforimmunoassaysnotspeciﬁcfor
insulin, whereas the HOMA SI calculator
is recommended for use with assays spe-
ciﬁcforinsulin,althoughnolimitsonany
cross-reactivity with proinsulin(s) are
speciﬁed.
A twofold difference in results from
insulin assays was reported in 1996 (4,5)
and conﬁrmed recently in the U.K. and
U.S. with newer insulin assays (6,7). The
U.K. study found that insulin values from
onespeciﬁcinsulinassaywere15%lower
in heparinized plasma than in serum.
Heparinized plasma was collected for the
HOMA database (1) and is frequently
used for research (3); however, serum is
more commonly used in practice for in-
sulinmeasurement.Thereisnoadvantage
intheuseofC-peptideratherthaninsulin
measurements for HOMA, as results from
different C-peptide assays vary and C-
peptide is not stable when stored (8). In
this study, HOMA estimates from 97
fasting subjects with normoglycemia,
pre-diabetes, or type 2 diabetes were
compared using 11 insulin assays to es-
tablish the extent to which the type of
blood sample collected, insulin assay se-
lected, or version of HOMA calculator
used affect HOMA estimates.
RESEARCH DESIGN AND
METHODS—Ethics approval was ob-
tained from the South East Wales Local
Research Ethics Committee, and the
study complied with the current revision
oftheDeclarationofHelsinki.Allpatients
gave written informed consent. A com-
parison of measurements from different
insulinassaysin150samplesfromfasting
(n99)andnonfastingsubjectstoreﬂect
the range for insulin in patients with dia-
betes has been published previously (6).
Fasting subjects (n  99), not strati-
ﬁed by age or sex, were recruited over
12-weeks with two excluded as their glu-
cose results at the time of the study did
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Participants with type 2 diabetes were
either being seen for a routine clinic
appointment or diagnostic oral glucose
tolerance test. Those with pre-diabetes or
normoglycemia were identiﬁed from
patient records or with the oral glucose
tolerance test.
Bloodsampleswerecollectedfromfast-
ing subjects, aged 18–75 years, either non-
diabetic (n  12; 12%), with pre-diabetes,
i.e., impaired fasting glucose or impaired
glucose tolerance (n  18; 19%), or with
type 2 diabetes (n  67; 69%) deﬁned by
the 1999 World Health Organization crite-
ria (9). Patients requiring insulin treatment
or known to be insulin antibody–positive
were excluded. Anonymized demographic
data were collected.
Collection of blood and laboratory
measurements
Blood samples were collected at the Dia-
betes Research Unit, Cardiff University,
Cardiff, U.K. (6). Plasma glucose was
measured in ﬂuoride oxalate samples
within 10 min of sampling using a Yellow
Springs analyzer (YSI2300; Yellow
Springs Instruments, Aldershot, U.K.).
Serum or heparinized plasma samples
were initially stored at 20°C for 1–2
days to ensure rapid freezing and then
transferredto70°C,proceduresroutine
forthislaboratoryandknownnottoaffect
insulin results. Samples were dispatched
on dry ice to laboratories in the U.K. and
U.S. No hemolyzed or lipemic samples
were collected. Samples were stored on
receipt at 20°C (or 70°C if available).
Insulin was measured in serum by 11
different insulin assays (6), shown in Ta-
ble 2, over 5 days or runs and in heparin-
ized plasma by one assay only. The
insulin assays are itemized in the order
followed in the tables and ﬁgure with
mean coefﬁcients of variation (trilevel
quality controls analyzed on ﬁve occa-
sions) (6) as follows: for serum, 1) Abbott
(AxSYM Insulin), 3.8%; 2) Bayer (ADVIA
Centaur Insulin), 5.6%; 3) Biosource-
Invitrogen (Insulin EASIA), 5.6%; 4) Da-
koCytomation (Insulin assay), 6.7%; 5)
DPC (Immulite 1000), 4.7%; 6) Linco
(U.S.) (ELISA), 6.4%; 7) Linco (U.S.)
(RIA), 4.5%; 8) Mercodia (Iso-Insulin as-
say [not speciﬁc for insulin]), 3.9%; 9)
MLT immunochemiluminometric assay),
5.1%; 10) Roche (Insulin E170), 1.4%;
11) Tosoh (Tosoh ST AIA-Pack IRI),
5.5%; and 12) Tosoh (U.S.) (Tosoh ST
AIA-Pack IRI), 2.5%; and for plasma, 13)
Biosource-Invitrogen (Insulin EASIA).
Only the Mercodia Iso-Insulin 10-
1128-01 assay was quoted by the manu-
facturer to have signiﬁcant cross-
reactivity with intact proinsulin (54%).
Statistical analysis
Data were analyzed using SAS (10) with
SI and RIA calculators (version 2.2, 30
June 2004; http://www.dtu.ox.ac.uk) for
HOMA estimates. HOMA version 2 was
recalibrated to give HOMA- and insulin
sensitivity (HOMA-S) of 100% in normal
young adults when assays available then
were used for insulin, speciﬁc insulin, or
C-peptide. In this study, the SI calculator
was used for 10 assays quoted as speciﬁc
for insulin and the RIA calculator was
used for one assay stated to cross-react
with proinsulin. As HOMA is based on
steady-state physiology, the model in-
cludes limits for glucose. Values outside
these limits, 3–25 mmol/l for both calcu-
lators (30 June 2004; http://www.dtu.ox
.ac.uk), are considered non–steady state
and HOMA is considered to be inappro-
priate. Input limits for insulin for the SI
calculator are 20–300 pmol/l and for RIA
calculator are 20–400 pmol/l. For Table
2, insulin values outside these ranges
were set to the values of the appropriate
limit. Corresponding results for HOMA
estimates when these results are excluded
are found in supplemental Table 1 (avail-
able in an online appendix at http://
dx.doi.org/10.2337/dc08-0097). Median
scoretests,i.e.,medianone-waynonpara-
metric ANOVA, were used in Table 2 to
test the signiﬁcance of differences in a
HOMA estimate derived from different
insulin assays in serum for a particular
glycemic state.
RESULTS—Normoglycemic partici-
pants (n  12) were aged 45.8  14.6
(mean  SD) years but were older if they
were pre-diabetic (n  18; 61.8  10.5
Table 1—Evolution of HOMA
Year Versions of HOMA Information on insulin assay
1985 HOMA: initial publication comprising equations approximating to
original computer model for estimation of HOMA- and
HOMA-S
For use in heparinized plasma with a competitive, insulin RIA
not speciﬁc for insulin (mU/l)
1998 Update of HOMA: computer programs for HOMA- and HOMA-
S that account for variations in hepatic and peripheral glucose
resistance, i.e., reduction in suppression of hepatic glucose
output by hyperglycemia and also peripheral glucose-
stimulated glucose uptake. Insulin secretion curve modiﬁed to
allow for increases in response to plasma glucose 10 mmol/l.
Model incorporates estimate of proinsulin secretion for use with
RIA and SI assays and renal glucose losses for hyperglycemic
subjects
For use with a competitive, immunoassay for
“immunoreactive” insulin and speciﬁc insulin (SI) assay
(mU/l) or C-peptide in heparinized plasma
2004 HOMA calculator version 2.1: released on 6 January 2004
2004 RIA and SI HOMA calculators version 2.2: released on 30 June
2004 for estimation of HOMA-IR in addition to HOMA- and
HOMA-S
RIA calculator for use in heparinized plasma with
RIA/competitive immunoassays that cross-react with
proinsulin(s) and SI calculator with SI assays (mU/l or
pmol/l)
Future HOMA-calculators: for estimation of all three HOMA variables For use with human insulin assays (pmol/l) with deﬁned
speciﬁcity, traceable to an RMP and international standard,
validated in serum and plasma
Factors affecting HOMA estimates
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59.8  9.5 years; P  0.0001). Most par-
ticipants were white Caucasian with one
of different ethnic origin in the pre-
diabetic group and two in the group with
type 2 diabetes. Half of the normoglyce-
mic subjects, one-third of those with pre-
diabetes, and 51 of 67 with type 2
diabetes were male. BMI was 27.9  5.2
kg/m
2 in the normoglycemic group, was
31.4  4.9 kg/m
2 in those with pre-
diabetes, and was similar in those with
diabetesat31.85.8kg/m
2.Themedian
durationofdiabeteswas4.5(interquartile
range [IQR] 0.5–7.0) years, with 25 pa-
tientsbeingtreatedwithdietaloneand42
taking oral antihyperglycemic agents.
Fastingplasmaglucosewas5.20.5
mmol/l, and median serum insulin (mea-
sured by 11 insulin assays) was 59 (IQR
38–78) pmol/l in normoglycemic sub-
jects, 6.2  0.4 mmol/l and 117 (54–
142) pmol/l for subjects with pre-
diabetes, and 8.4  2.2 mmol/l and 86
(46–142) pmol/l for type 2 diabetic sub-
jects. A P value of 0.07 was obtained from
aKruskal-Wallistestforinsulinacrossthe
groups. HOMA- was highest in those
with pre-diabetes at 109% (71–149),
lower in those with normoglycemia at
85% (64–128), and lowest in those with
type 2 diabetes at 63% (38–88) (P 
0.0002). HOMA-IR was 1.30 (0.84–
1.65) in normoglycemic subjects, highest
in subjects with pre-diabetes at 2.58
(1.24–3.12), and slightly lower in dia-
betic subjects at 2.13 (1.19–3.54) (P 
0.022). Values for HOMA-S were 82%
(67–137) for normoglycemic subjects,
40% (33–84) in those with pre-diabetes,
and 50% (29–93) in those with diabetes
(P  0.025).
Percentage of patients with data
outside input limits for HOMA
calculators
All glucose values obtained were appro-
priate for the HOMA calculator version
2.2. However, 4.3% of insulin results (55
in total) were 20 pmol/l, and 1% (12 in
total) were 300 pmol/l and, therefore,
werenotaccepted.Theactualnumbersof
insulinvaluesoutsidelimitsforeachassay
can be seen in supplemental Table 2
(availableintheonlineappendix).HOMA
estimates are presented in Fig. 1; both in-
clusionofparticipantswithinsulinvalues
set to HOMA limits if outside these limits
and exclusion if outside limits are shown.
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DIABETES CARE, VOLUME 31, NUMBER 9, SEPTEMBER 2008 1879Figure 1—HOMA estimates by assay (order as in Table 2) in participants with normoglycemia, pre-diabetes, or type 2 diabetes. Plots on the top
include all participants and plots directly below include only those with data within HOMA limits from all assays. Box and whisker plots are shown
with bottom and top edges of the box located at sample 25th and 75th percentiles, the center horizontal line drawn at the 50th percentile (median),
andverticallinesorwhiskersdrawnfromtheboxtothemostextremepointwithin1.5IQRs.Moreextremevaluesaremarkedwith(1.5and3
IQR) or * (3 IQR). The SI calculator was used for all assays except Mercodia.
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For illustrative purposes only, the RIA
calculator rather than SI calculator was
used with assays speciﬁc for insulin; esti-
mates of HOMA- differed by 11% (P 
0.0001) and of HOMA-IR by 15% (P 
0.0001).
HOMA estimates from serum and
plasma
Thecorrespondingvaluesforestimatesin
heparinized plasma versus serum can be
seeninTable2.Itisimportanttonotethat
the insulin assay used in plasma had a
high bias compared with the other assays
(6), which was reﬂected in the estimates.
HOMA estimates vary depending on
insulin assay
The distribution of HOMA estimates for
each insulin assay is presented by glyce-
mic status in Fig. 1 and Table 2. HOMA
estimates varied by up to twofold, de-
pendingonwhichinsulinassaywasused.
CONCLUSIONS —HOMA is widely
used as a research tool in epidemiological
studies in which invasive techniques for
modelingsuchasintravenousglucosetol-
erance testing are not practical (3).
HOMAisnotapplicableforindividualpa-
tient care as insulin results from different
laboratories may vary (4). We have com-
piled a checklist of procedures to follow
when HOMA is used (Table 3). In this
study, the ﬁrst ﬁve were fulﬁlled but only
one blood sample was collected. For the
original model, three blood samples were
collected 5 min apart to account for insu-
lin pulsatility, although HOMA estimates
have been published subsequently from
one sample in large research or epidemi-
ological studies.
When HOMA estimates from this
study are compared with those reported
previously, it is important to note that
they reﬂect the population studied, i.e., a
small sample size with participants being
mostly white Caucasian, being older than
those recruited for HOMA (version 2),
and having higher BMI. From an analyti-
cal point of view, differences in conver-
sion factors quoted for an insulin assay,
ranging from 6.0 to 7.46 (6), will also
contributetovariation.TheHOMAcalcu-
lator version 2.2 accepts international or
molar units for insulin and uses a con-
version factor of 6.9 (microunits per
milliliter to picomoles per liter). The
American Diabetes Association Working
Group recommends a factor of 6.0 (7).
The study does not address the question
of long-term stability of assays as insulin
was measured over a very short period
using a particular batch of reagents and
calibrator.
All glucose results were within limits
for HOMA version 2.2, but 5% of insulin
values fell outside with 4% below the
lower limit (supplemental Table 1). It is
interesting to note that there is no com-
mon policy among HOMA users on how
to handle insulin results outside limits.
Values can be excluded from the statisti-
cal analysis or set to limits; this may have
affected results of published studies and
have clinical implications. Until a new
version of HOMA is developed that ac-
ceptsthemajorityofinsulinvaluesgener-
ated by current assays, the quandary will
continue. When reporting HOMA esti-
mates, authors should state how these re-
sults are treated in the statistical analysis
section of their article.
HOMA estimates from serum and
heparinized plasma differ, reﬂecting the
lower insulin values found in plasma (6).
AlthoughHOMAcalculatorsarebasedon
heparinized plasma collected under re-
search conditions, serum is more widely
used. Other sample types, e.g., EDTA
plasma, may offer some beneﬁts in terms
of sample stability (11,12), but more in-
formation is required on the effects of an-
ticoagulants and clot accelerators on
insulin immunoassays .
The decision on which HOMA calcu-
lator to use may not be self-evident. The
RIA model was developed with an RIA
that demonstrated 100% cross-reactivity
with proinsulin, but the RIA in this study
is reported to be speciﬁc for insulin. Like-
wise, the SI calculator is recommended
for assays that do not cross-react with
proinsulin(s), yet recently an American
Diabetes Association Task Force demon-
strated that some immunometric assays
described as “speciﬁc” show signiﬁcant
Figure 1—Continued
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causeofthelackofavailabilityofdifferent
proinsulin species, published data on
cross-reactivity are sparse. Later versions
of HOMA incorporate an estimate of pro-
insulin secretion for speciﬁc insulin as-
says, although this will not account for
variation in the extent and nature of the
cross-reactivity. Depending on glycemic
status, proinsulin will account for 10 to
20% of “immunoreactive insulin” (13).
When mean values from speciﬁc insulin
assays were entered into the RIA calcula-
torratherthantheSIcalculator,estimates
were different from those obtained from
the SI calculator, but the differences were
rectiﬁed when mean speciﬁc insulin plus
total proinsulin were entered into the RIA
calculator (14).
Differences in HOMA estimates due
to sample type and calculator version are
small compared with the twofold differ-
ence in extremes of values reported by
insulin assays. Difference plots for an in-
sulin assay (6) versus the mean of assays
(as no reference measurement procedure
[RMP] was available) showed offsets or
positive or negative concentration-
dependent differences. This has been
conﬁrmedbyarecentstudy(16)compar-
ing immunoassays to isotope dilution,
liquid chromatography/tandem mass
spectrometry. A corresponding pattern of
differencesinHOMAestimateswasfound
inthisstudywiththedirectiondepending
on the nature of the transform required
for the particular estimate (15) (supple-
mentalmaterialavailableintheonlineap-
pendix). Ranking of insulin results was
maintained in the different insulin assays
(r
2 0.983–0.997) (6) with this level of
ranking broadly maintained for HOMA
estimates in this study.
All insulin assays were quoted as be-
ing calibrated using International Refer-
ence Preparation (IRP) 66/304, but
differences in calibration procedures and
IRP commutability, assay format, speci-
ﬁcity, and conversion factors may have
contributed to assay bias (6). In the ab-
senceofanRMP,varioustacticshavebeen
introducedtoreducevariation,e.g.,using
a central laboratory with the same meth-
odology throughout (17,18), sample ex-
changes (19), and ranking HOMA
estimates from different assays (20), al-
though these have limited applicability.
To achieve standardization for insulin, an
RMP and commutable reference material
or certiﬁed serum calibrator producing
traceable results to a deﬁned measurand
expressed in SI units are required.
Progress has been made with publication
of an isotope dilution, liquid chromatog-
raphy/tandemmassspectrometrymethod
(21,16) for serum insulin. However, es-
tablishment of traceability for HOMA has
yet to be attained.
In common with other means of as-
sessing insulin resistance or -cell func-
tion, comparison among studies is
problematic. Estimates cannot be com-
pared if different insulin assays are in-
volved nor can cut points be established
across populations. In addition, they are
Table 3—Questions to ask before using HOMA version 2.2
Questions Answers
Do subjects need to be fasting? Yes.
Can patients treated with insulin be included? No.
Should patients take oral hypoglycemic
agents on day of HOMA?
Yes, but after blood collection for HOMA.
Can insulin antibody–positive patients be
included?
No, as insulin antibodies affect insulin measurements.
Can hemolyzed samples be used? No, as insulin is degraded by enzymes released by red blood cells.
How should blood be collected? Three heparinized blood samples 5 min apart for HOMA database, but single
samples are now taken in some circumstances. HOMA estimates from
serum and heparinized plasma differ and cannot be compared directly.
Can any insulin immunoassay be used? HOMA estimates from different insulin assays cannot be compared directly
as they can differ by up to 100%. Particular assays were not identiﬁed for
the different versions of HOMA. Assay performance, both internal and
external, should be evaluated because limitations documented (7).
Should assay be speciﬁc for insulin? Most assays are speciﬁc for insulin, a requirement for traceability. The RIA
calculator is available for nonspeciﬁc assays, but use of these assays is
limited by lack of data on cross-reactivity with split proinsulin(s) and
extent.
How should insulin or fasting plasma glucose
(FPG) values be entered if outside limits for
HOMA calculators?
Insulin values should be set to lower or upper limits for HOMA calculators
as estimates of central tendency and dispersion will be affected if subjects
are excluded if insulin values outside these limits. With current insulin
assays, 4% of insulin values were below the HOMA lower limit and 1%
were above the upper limit. FPG below the lower limit should not be used
as hypoglycemia is a non–steady state not suitable for this steady-state
model, or there has been a problem with the sample or its measurement.
Is there a reference material and method for
human insulin commutable to current
assays?
Currently all assays are standardised with the same reference preparation
(IRP 66/304); however, results still vary by up to a factor of 2. Candidate
RMPs have been published.
Are there reference ranges for HOMA
estimates for different insulin assays?
No, HOMA estimates differ, depending on the insulin assay used. HOMA
estimates are reported as a percentage of “normal;” therefore, normality
should be deﬁned for a population.
Factors affecting HOMA estimates
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version. The SI calculator recommended
for assays that do not cross-react with
proinsulinincludesafactortoaccountfor
physiological actions of proinsulin. Not
all immunometric assays demonstrate
this degree of speciﬁcity (7). The RIA cal-
culator should be used for assays that
cross-react 100% with proinsulin what-
ever the assay architecture. Although di-
rect comparison of numerical results of
HOMA estimates may not be valid, it is
validtolookatrelativechangesortocom-
pare their distribution across populations.
In summary, until a new HOMA ver-
sionbasedonaninsulinassaytraceableto
an RMP with appropriate standards for
serum and plasma is developed, this
study provides the most reliable informa-
tion on estimates from different sources.
Selection of the appropriate HOMA cal-
culator for the insulin assay is essential.
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